Document:

Exhibit 10.4

 

THIS WARRANT AND THE UNDERLYING SECURITIES
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

ELECTROMEDICAL TECHNOLOGIES, INC.

 

WARRANT TO PURCHASE COMMON STOCK

 

	No. W-2	May 1, 2020

VOID AFTER MAY 1, 2025

 

THIS CERTIFIES THAT, for value received, AGILITY FINANCIAL PARTNERS,
LLC or assigns (the “Holder”), is entitled to subscribe for and purchase from Electromedical Technologies, Inc.,
a Delaware corporation (the “Company”), the Exercise Shares (as defined below) of the Company’s Common Stock on
the terms and subject to the conditions set forth below. This Warrant is being issued in connection with that certain Consulting
Agreement among the Company and the consultants party thereto dated as of September 7, 2016 (the “Consulting Agreement”).

 

DEFINITIONS. As used herein, the following terms shall have
the following respective meanings:

 

(a)           “Acquisition” shall
mean either (A) a merger, consolidation, equity sale or similar transaction involving (directly or indirectly) the Company upon
which, immediately after the consummation of the transaction, the shareholders of the Company immediately prior thereto do not
own, directly or indirectly, either (i) voting securities representing more than 50% of the combined voting power of the surviving
entity in such transaction, or (ii) securities representing more than 50% of the combined voting power of the parent of the surviving
entity in such transaction; or (B) a sale, lease, transfer, exclusive license or other disposition, in a single transaction or
series of related transactions, of all or substantially all of the assets of the Company.

 

(b)           “Exercise Period” shall mean the period
commencing with the date hereof and ending on May 1, 2025, unless sooner terminated as provided below.

 

(c)           “Exercise Price” shall mean $0.52 per
Exercise Share subject to adjustment pursuant to Section 5 below.

 

(d)           “Exercise Shares” shall mean up to 100,000
shares of the Company’s Common Stock issuable upon exercise of this Warrant, subject to adjustment pursuant to the terms herein.

 

(e)           “IPO” shall mean the Company’s first firm
commitment underwritten offering and sale of the Company’s Common Stock (the “Common Stock”) to the public pursuant
to an effective registration statement under the Securities Act of 1933, as amended (the “Act”).

 

    	 

     

    

 

		2.	EXERCISE OF WARRANT

 

(a)           The rights represented by this Warrant may be exercised
in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth
on the signature page hereto (or at such other address as it may designate by notice in writing to the Holder):

 

(i) An executed Notice of Exercise in the form attached hereto;

 

(ii) Payment of the Exercise Price either in cash or by check;
and

 

(iii) This Warrant.

 

Upon the exercise of the rights represented by this Warrant,
a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated
with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights
represented by this Warrant shall have been so exercised. In the event that this Warrant is being exercised for less than all of
the then-current number of Exercise Shares purchasable hereunder, the Company shall, concurrently with the issuance by the Company
of the number of Exercise Shares for which this Warrant is then being exercised, issue a new Warrant exercisable for the remaining
number of Exercise Shares purchasable hereunder.

 

The person in whose name any certificate or certificates for
Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares
on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery
of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books
of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the
next succeeding date on which the stock transfer books are open.

 

(b)           Net Exercise. In lieu of cash exercising this Warrant, the
Holder of this Warrant may elect to receive shares equal to the value of this Warrant (or the portion thereof being canceled) by
surrender of this Warrant at the principal office of the Company together with notice of such election, in which event the Company
shall issue to the holder hereof a number of Shares computed using the following formula: X = Y (A-B) A Where X = the number of
shares of Common Stock to be issued to Holder. Y = the number of shares of Common Stock purchasable under the Warrants being exchanged
(as adjusted to the date of such calculation). A = the Market Price on the date of receipt by the Company of the exercise documents.
B = the Exercise Price of the Warrants being exchanged (as adjusted in accordance with the terms hereof). The “Market Price”
on any trading day shall be deemed to be the average of the ask and bid price of the Common Stock over the five (5) trading days
immediately preceding receipt by the Company of the exercise documents as officially reported by the principal securities exchange
or quotation medium on which the shares of Common Stock are listed or eligible for trading. If the Market Price cannot be determined
pursuant to the sentence above, the Market Price shall be determined in good faith (using customary valuation methods) by the Board
of Directors of the Company based on the information best available to it, including recent arms-length sales of Common Stock to
unaffiliated persons.

 

    	 

     

    

 

If, within six (6) months from the date of this Warrant, the
Holder sells the Exercise Shares and receives, net of commissions, amounts outstanding due from Company, up to a maximum of $100,000,
the Holder shall forgive the Debt owed to it by the Company and which shall be deemed paid in full up to the maximum. If that does
not occur within six months of the date of this Warrant, the Debt shall remain in full force and effect, regardless of when the
Holder is able to sell the Exercise Shares.

 

		3.	COVENANTS OF THE COMPANY.

 

3.1           Covenants as to Exercise Shares. The Company covenants
and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant and the shares
of the Company’s Common Stock that may be issued upon conversion of the Exercise Shares will, upon issuance, be validly issued
and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof.
The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved,
free from preemptive rights, a sufficient number of shares of the series of equity securities comprising the Exercise Shares to
provide for the exercise of the rights represented by this Warrant and a sufficient number of shares of the Company’s Common Stock
to provide for the conversion of the Exercise Shares. If at any time during the Exercise Period the number of authorized but unissued
shares of such series of the Company’s equity securities shall not be sufficient to permit exercise of this Warrant or the conversion
of the Exercise Shares, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase
its authorized but unissued shares of such series of the Company’s equity securities to such number of shares as shall be sufficient
for such purposes.

 

3.2           Notices of Record Date. In the event of any taking
by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, the Company shall mail to the Holder, at least 10 days prior to the date
specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution.

 

		4.	REPRESENTATIONS OF HOLDER.

 

4.1           Acquisition
of Warrant for Personal Account. The Holder represents and warrants that it is acquiring the Warrant and the Exercise Shares
solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or
any part thereof. The Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise Shares
the Holder is acquiring is being acquired for, and will be held for, its account only.

 

4.2           Securities
Are Not Registered.

 

(a)           The
Holder understands that the Warrant and the Exercise Shares have not been registered under the Act on the basis that no distribution
or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not
be present if, notwithstanding its representations, the Holder has a present intention of acquiring the securities for a fixed
or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in,
or otherwise distributing the securities. The Holder has no such present intention.

 

    	 

     

    

 

(b)           The
Holder recognizes that the Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered under
the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register
the Warrant or the Exercise Shares of the Company, or to comply with any exemption from such registration.

 

(c)           The
Holder is aware that neither the Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless
certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of
certain current public information about the Company, the resale following the required holding period under Rule 144 and the
number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions
for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions
in the foreseeable future.

 

4.3           Disposition of Warrant and Exercise Shares.

 

(a)           The
Holder further agrees not to make any disposition of all or any part of the Warrant or Exercise Shares in any event unless and
until:

 

(i)           The
Company shall have received a letter secured by the Holder from the Securities and Exchange Commission stating that no action
will be recommended to the Commission with respect to the proposed disposition;

 

(ii)          There
is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance
with said registration statement; or

 

(iii)         The
Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement
of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished
the Company with an opinion of counsel, reasonably satisfactory to the Company, for the Holder to the effect that such disposition
will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws. The Company
agrees that it will not require an opinion of counsel with respect to transactions under Rule 144 of the Securities Act of 1933,
as amended, except in unusual circumstances.

 

(b)           The Holder understands and agrees that all certificates
evidencing the shares to be issued to the Holder may bear the following legend:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.

 

    	 

     

    

 

4.4           Accredited Investor Status. The Holder is an “accredited
investor” as defined in Regulation D promulgated under the Act.

 

		5.	ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF EXERCISE
SHARES.

 

5.1           Changes
in Securities. In the event of changes in the series of equity securities of the Company comprising the Exercise Shares by
reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations,
liquidations, or the like, the number and class of Exercise Shares available under the Warrant in the aggregate and the Exercise
Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price,
the total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and
had the Holder continued to hold such shares until after the event requiring adjustment. For purposes of this Section 5, the “aggregate
Exercise Price” shall mean the aggregate Exercise Price payable in connection with the exercise in full of this Warrant.
The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.
Whenever the Exercise Price or the number of shares of Exercise Shares purchasable hereunder shall be adjusted pursuant to this
Section 5.1, the Company at its expense shall issue a certificate signed by an authorized officer setting forth, in reasonable
detail, the event requiring the adjustment or readjustment, the amount of the adjustment or readjustment and the Exercise Price
and number of shares purchasable hereunder after giving effect to such adjustment or readjustment, and shall cause a copy of such
certificate to be mailed (by first-class mail, postage prepaid, or overnight delivery service) to the Holder of the Warrant. The
Company shall, upon the written request of the Holder of the Warrant at any time, furnish or cause to be furnished to such Holder
a like certificate setting forth: (i) all such adjustments and readjustments that have been effected under the Warrant; (ii) the
Exercise Price at the time in effect and (iii) the number of shares of Exercise Shares, the type of Exercise Shares and the amount,
if any, of other property that at the time would be received upon the exercise of the Warrant.

 

5.2           Automatic Conversion. Upon the automatic conversion
of all outstanding shares of the series of equity securities comprising the Exercise Shares, this Warrant shall become exercisable
for that number of shares of Common Stock of the Company into which the Exercise Shares would then be convertible, so long as such
shares, if this Warrant had been exercised prior to such offering, would have been converted into shares of the Company’s Common
Stock pursuant to the Company’s Certificate of Incorporation. In such case, all references to “Exercise Shares” shall
mean shares of the Company’s Common Stock issuable upon exercise of this Warrant, as appropriate.

 

6.           FRACTIONAL SHARES. No fractional shares shall be issued upon
the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) to be
issued upon exercise of this Warrant shall be aggregated for purposes of determining whether the exercise would result in the issuance
of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall,
in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product
resulting from multiplying the then current fair market value of one Exercise Share by such fraction.

 

    	 

     

    

 

7.           NOTICE OF ACQUISITION. In the event of, at any time during
the Exercise Period, an IPO or an Acquisition, the Company shall provide to the Holder 30 days’ advance written notice of such
IPO or Acquisition.

 

8.           MARKET STAND-OFF AGREEMENT. Holder hereby agrees that Holder
shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or
similar transaction with the same economic effect as a sale, any shares of Common Stock (or other securities) of the Company held
by Holder (other than those included in the registration) (i) during the 180-day period following the effective date of the IPO
(or such longer period as the underwriters or the Company shall request in order to facilitate compliance with FINRA Rule 2711
or NYSE Member Rule 472 or any successor or similar rule or regulation), and (ii) the 90-day period following the effective date
of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company
shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or
regulation); provided, that, with respect to (i) and (ii) above, all officers and directors of the Company and holders of at least
one percent of the Company’s voting securities are bound by and have entered into similar agreements. Holder agrees that any transferee
of the Warrant (or other securities) of the Company held by Holder shall be bound by this Section 8. The underwriters of the Company’s
stock are intended third party beneficiaries of this Section 8 and shall have the right, power and authority to enforce the provisions
hereof as though they were a party hereto.

 

9.           NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall
not entitle the Holder to any voting rights or other rights as a stockholder of the Company.

 

10.         TRANSFER
OF WARRANT. This Warrant and all rights hereunder are not transferable by the Holder other than, for a Holder that is a partnership,
limited liability company, corporation, or venture capital fund, to (i) a partner of such partnership, a member of such limited
liability company, or stockholder of such corporation, (ii) an affiliate of such partnership, limited liability company or corporation
(including, any affiliated investment fund of such Holder), (ii) a retired partner of such partnership or a retired member of
such limited liability company, or (iii) the estate of any such partner, member, or stockholder (such transfer, an “Affiliate
Transfer” and such transferees an “Affiliate Transferee”).

 

Affiliate Transfers may be made upon delivery of this Warrant
and the form of assignment attached hereto to any Affiliate Transferee designated by Holder. The Company represents that it has
taken all action necessary to exempt an Affiliate Transfer from any such applicable transfer restrictions. The Affiliate Transferee
shall sign an investment letter in form and substance satisfactory to the Company.

 

11.         LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant
is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose
(which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and
tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation
of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 

    	 

     

    

 

12.         AMENDMENT. Any term of this Warrant may be amended or waived
with the written consent of the Company and Holder.

 

13.         NOTICES, ETC. All notices required or permitted hereunder
shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent
by confirmed facsimile or email if sent during normal business hours of the recipient, if not, then on the next business day, (c)
five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent to the Company at the address listed in the Consulting Agreement or at such other address as the Company
or Holder may designate by 10 days’ advance written notice to the other parties hereto.

 

14.         ACCEPTANCE. Receipt of this Warrant by the Holder shall
constitute acceptance of and agreement to all of the terms and conditions contained herein.

 

15.         GOVERNING LAW. This Warrant and all rights, obligations
and liabilities hereunder shall be governed by and construed under the laws of the State of Delaware as applied to agreements among
Delaware residents, made and to be performed entirely within the State of Delaware without giving effect to conflicts of laws principles.

 

16.         REGISTRATION RIGHTS. If the Company grants, or has granted,
any other person or entity registration rights with respect to the Common Stock of the Company, then the Company shall enter into
a substantially similar registration rights agreement with Holder with respect to the Exercise Shares, granting such Exercise Shares
pari passu registration rights.

 

    	 

     

    

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be
executed by its duly authorized officer as of the date first set forth above.

 

	HOLDER:	COMPANY:
	 	 
	 	 
	 	 
	Agility Financial Partners, LLC	Electromedical Technologies, Inc.
	 	 
	 	 
	 	 
	By: Cindy Solovei                  	By: Matthew Wolfson             
	       Cindy Solovei, Partner	       Matthew Wolfson, CEO

 

 

 

 

[SIGNATURE PAGE]

 

    	 

     

    

 

NOTICE OF EXERCISE

 

TO: ELECTROMEDICAL TECHNOLOGIES, INC.

 

(1) The undersigned hereby elects to purchase                     shares
of                               (the
 “Exercise Shares”) of ELECTROMEDICAL TECHNOLOGIES, INC. (the “Company”) pursuant to the terms of the
attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
If this is a Net Exercise pursuant to Section 2(b), check here: ______

 

(2) Please issue a certificate or certificates representing
said Exercise Shares in the name of the undersigned or in such other name as is specified below:

 

                                                                

(Name)

 

                                                               

                                                               

(Address)

 

(3) The undersigned represents that (i) the aforesaid Exercise
Shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection
with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii)
the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about
the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced
in making investments of this type and has such knowledge and background in financial and business matters that the undersigned
is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned
understands that Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933,
as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities
Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and,
because such securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered
under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid Exercise
Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned
has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability
of current information to the public about the Company and the Company has not made such information available and has no present
plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of Exercise
Shares unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition
and such disposition is made in accordance with said registration statement, or, if reasonably requested by the Company, the undersigned
has provided the Company with an opinion of counsel, if requested, satisfactory to the Company, stating that such registration
is not required.

 

    	 

     

    

 

	 	 	 
	(Date)	 	(Signature)
	 	 	 
	 	 	 
	 	 	(Print name)

 

 

    	 

     

    

 

ASSIGNMENT

FORM

 

	 	(To assign the foregoing Warrant, execute this form and supply
required information. Do not use this form to purchase shares.)	 

 

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights
evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please
	 	 
	Address	 
	 	Print)
	 	 
	 	 
	 	(Please
	 	 
	 	 
	 	Print)

 

 

Dated:                          ,
20__ 

 

Holder’s

 

Signature:                                                                     

 

Holder’s

Address:                                                          

 

 

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations
and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing
Warrant.Exhibit 10.9 

 

SPECIAL
MEETING & RESOLUTION OF THE DIRECTORS

 

ELECTROMEDICAL TECHNOLOGIES, INC.

A Delaware Corporation

 

The undersigned, being all
the Directors of Electromedical Technologies, Inc., a Delaware Corporation (the “Company”), hereby adopt the following
recitals and resolutions after the holding of a Special Meeting of the Board of Directors pursuant to Section 3.7 of the Company’s
By Laws, effective as of October 21, 2019, the Directors hereby waiving all notice of, and the holding of, a meeting of the directors
to act upon such matters and resolutions, pursuant to the General Delaware Corporation Law and the Company’s By-Laws. Notice
of the Special Meeting having been waived verbally by all the Directors present at the Special Meeting, a quorum was found to be
present sufficient to conduct business.

 

RECITALS

 

WHEREAS,
on July 9, 2018, the Company entered into a (i) Independent Contractor Services Agreement; (ii) Side Letter; and, (iii) KISS Note
with Blue Ridge Enterprises, LLC, a California Limited Liability Company (“Blue Ridge”) (the “Transaction Documents”).
Copies of the Transaction Documents are appended hereto and incorporated herein by reference.

 

WHEREAS, as consideration for securing Blue
Ridge’s consulting services, the Company executed the KISS Note (Section 4(a) on page 2 of the Consulting Agreement).

 

WHEREAS,
the KISS Note was executed on July 6, 2018 when Blue Ridge paid the purchase price of $35,000 to the Company.

 

WHEREAS,
pursuant to Section 2.3 of the KISS Note, Blue Ridge may at any time after the Company’s common stock is quoted on the OTC
Markets Listing Service, convert any or all the KISS Note into shares of the Company’s common stock calculated by dividing
the conversion amount by the conversion price.

 

WHEREAS,
the Company was listed on the OTC Markets Listing Service on June 17, 2019 under the symbol “ELCQ,” having successfully
completed its 15c-2-11 filing with its sponsor Glendale Securities, and by operation of Section 2.3, Blue Ridge could exercise
its conversion rights.

 

WHEREAS,
Blue Ridge communicated to the Company its desire to convert a portion of the KISS note equal to one million (1,000,000) common
shares. The Company calculated the number of available conversion shares, based upon the quotient obtained by dividing the conversion
amount by the conversion price. As disclosed in the Company’s Form 1-SA filed with the Securities and Exchange Commission
on September 19, 2019, the Company calculated the number of conversion shares available to Blue Ridge to be 8,189,874 shares.

 

WHEREAS,
pursuant to Section 2 of the Side Letter, Blue Ridge communicated its intent to sell a portion of all of the conversion shares
issuable hereunder to third parties. The Company confirms that it refused its rights of first refusal to purchase the conversion
shares from Blue Ridge.

 

    1

     

    

 

WHEREFORE, for good cause appearing, the Company:

 

HEREBY
RESOLVES: to issue one million (1,000,000) common shares to Blue Ridge Enterprises, LLC; address: 5256 South Mission Road,
Ste. 104, Bonsall, CA 92003; Federal EIN: 83-0860649, said shares to be issued in book entry form; and,

 

FURTHER
RESOLVES: that pursuant to Section 4(b) of the Consulting Agreement, the one million (1,000,000) common shares issued to
Blue Ridge pursuant to this Resolution, shall be deemed earned and beneficially owned as of the effective date of the consulting
agreement, July 9, 2018.

 

RESOLVED
FURTHER, the appropriate Officers of the Company be, and they hereby are, authorized and empowered to execute such documents,
take such steps and perform such acts as, in their judgment, may be necessary or convenient in carrying out the foregoing resolutions
consistent with the Company’s By Laws, including placing this Resolution in the appropriate Books and Records of the Company,
and that any such documents executed or acts taken by them shall be conclusive evidence of authority in so doing.

 

IN
WITNESS WHEREOF, the undersigned have executed this Resolution as of date first written above.

 

	ALL DIRECTORS OF ELECTROMEDICAL TECHNOLOGIES, INC.
	 	 
	 	 
	 	 
	 	MATTHEW N. WOLFSON
	 	 
	 	DIRECTOR, CHAIRMAN

 

    2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]